Significantly more patients were relapse-free with TECFIDERA vs placebo in 2-year pivotal trials1

Further studied in real-world and newly diagnosed analyses

Results in patients who switched to TECFIDERA from Copaxone®4

Explore this study

TECFIDERA efficacy vs interferons, Copaxone®, Aubagio®, and Gilenya®5

Explore this analysis

Data on newly diagnosed patients at 2 years6

Explore this analysis

Backed by patient support and coverage

Patient support on starting treatment and managing common side effects

Explore support services

87% first-line coverage2‡
Copay Program for eligible patients

Explore access

There are many things to consider when helping your patients get started on therapy. Learn more.